Preclinical and clinically-based studies have shown beneficial responses to be highly dependent on the induction and functional activity of cytotoxic CD8+ T lymphocytes, which recognize tumor antigen(s) expressed by tumor cells. This evidence concerns the gene CD8A and neoplasm.